Parkinson’s disease genes activated in zebrafish exposed to aluminium

News

Author: Scarlett SherriffPublished: 4 August 2022

Prep: Cook: Serves:

According to research on zebrafish in Naples, Italy, aluminium exposure may increase the activity of several genes associated with the development of Parkinson’s.

The team investigated the impact of exposing zebrafish to aluminium for periods of 10, 15 or 20 days. Subsequent analyses revealed that effects in “cellular disorganisation” and swelling, brought on by the exposure, were highest after 10 or 15 days – and that around 10 Parkinson’s-related genes showed increased signs of activation.

The researchers found that while fish exposed to aluminium showed signs of brain degeneration, brain tissue remained intact in the fish that were not exposed.

When their results were published in the journal ‘Chemosphere’, the researchers noted that further investigation of the link between aluminium exposure and Parkinson’s is needed – but they wrote: “Overall, the data confirm the neurotoxicity induced by aluminium and shed a light on its involvement in neurodegenerative processes.”

Read more about the study on aluminium exposure and Parkinson’s genes.

For more information on the latest Parkinson’s research, please visit Parkinson’s Europe website.

Co-existing conditions may impact how people with Parkinson’s perceive stigma.

Last Month

Next Month

Go Back

Share this story

Comments

News

Antidepressants and anti-anxiety drugs may be linked to Parkinson’s disease risk in older women

A recent study from scientists in the US and Saudi Arabia has revealed th

New study identifies possible markers of inflammation linked to Parkinson’s disease

Researchers based in Germany and the US may have identified a way to detect

Heart problems linked to dementia risk in Parkinson’s disease, say researchers

Researchers at the University of Turin, Italy, have identified that Parkins

Investigational Parkinson’s disease dementia therapy fails in clinical trial

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…

A new intimacy guide aims to support people with Parkinson’s disease in the US

Does sexual wellness in the Parkinson’s community need more focus? It’s an area that the American Parkinson Disease Association (APDA) and media brand Havas Health Plus have targeted through the launch of a free intimacy guide. Available to people in the US, ‘The ParkinSex Booklet & Kit’ aims to support those whose relationships may have been impacted by emotional and physical distance linked to the condition. Alongside an educational guide, the kit includes items such as candles, coupons for adaptative clothing and massage stones. Following a positive response to an initial pilot distribution of the guides in the US, there is now a waitlist for future kits. Commenting on the launch in a press release, APDA president and CEO Leslie Chambers said: “The challenges of Parkinson’s can often result in intimacy and connection getting left behind. This is why we created ‘The ParkinSex Booklet & Kit’, to help people with…

How prevalent are non-visual hallucinations in Parkinson’s disease?

Some people in the later stages of Parkinson’s can experience hallucinations – “when you see, hear or feel things that aren’t there”. With most research into this topic centred on visual hallucinations, a team in Australia set out to investigate data around non-visual hallucinations in people with the condition. Published in the ‘Journal of Neurology’, the analysis drew on 91 relevant studies released between 1970 and 2022. The team found that visual hallucinations appeared to be most common, with an expected prevalence of up to 96.6%. Meanwhile, non-visual hallucinations – including auditory (relating to the sense of hearing) and olfactory (relating to the sense of smell) – had an estimated prevalence of up to 73.3%. Concluding that non-visual hallucinations may “impact a notable proportion” of people with the condition, the team said: “More direct research and clinical attention need to be devoted to the study and management of such hallucinatory…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Parkinson’s disease genes activated in zebrafish exposed to aluminium

News

Author: Scarlett SherriffPublished: 4 August 2022

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

News

Antidepressants and anti-anxiety drugs may be linked to Parkinson’s disease risk in older women

News

New study identifies possible markers of inflammation linked to Parkinson’s disease

News

Heart problems linked to dementia risk in Parkinson’s disease, say researchers

Investigational Parkinson’s disease dementia therapy fails in clinical trial

A new intimacy guide aims to support people with Parkinson’s disease in the US

How prevalent are non-visual hallucinations in Parkinson’s disease?

{title}

Subscribe

Parkinson’s disease genes activated in zebrafish exposed to aluminium

News

Author: Scarlett SherriffPublished: 4 August 2022

Last Month

Next Month

Share this story

Comments

Related articles

News

Antidepressants and anti-anxiety drugs may be linked to Parkinson’s disease risk in older women

News

New study identifies possible markers of inflammation linked to Parkinson’s disease

News

Heart problems linked to dementia risk in Parkinson’s disease, say researchers

Investigational Parkinson’s disease dementia therapy fails in clinical trial

A new intimacy guide aims to support people with Parkinson’s disease in the US

How prevalent are non-visual hallucinations in Parkinson’s disease?

{title}

Subscribe

Sign in